Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Rui Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2725-1574; OpenAlex author ID A5091664811; NIH RePORTER profile ID 10393266. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 2)
Trials
0
Grants
1
Labs led
3
Collaborators
28
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 9 papers · 2022: 1 paper · 2023: 3 papers, 1 grant · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 22

  1. Ferroptosis in pancreatic ductal adenocarcinoma: Mechanisms, tumor biology, and therapeutic opportunities. Co-author DOI 10.1016/j.canlet.2026.218788↗
  2. CYP51A1 drives resistance to pH-dependent cell death in pancreatic cancer. Co-author DOI 10.1038/s41467-025-57583-2↗
  3. AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer. Last author DOI 10.1126/scitranslmed.adp4986↗
  4. Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells. Co-author DOI 10.20517/cdr.2025.103↗
  5. ACSS2-mediated NF-κB activation promotes alkaliptosis in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-023-28261-4↗
  6. EP300 promotes ferroptosis via HSPA5 acetylation in pancreatic cancer. Co-author DOI 10.1038/s41598-023-42136-8↗
  7. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adg3049↗
  8. Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1007/s11307-022-01704-6↗
  9. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. First author DOI 10.1002/cac2.12188↗
  10. MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Last author DOI 10.1016/j.chembiol.2021.01.006↗
  11. Targeting ferroptosis in pancreatic cancer: a double-edged sword. First author DOI 10.1016/j.trecan.2021.04.005↗
  12. Cell death in pancreatic cancer: from pathogenesis to therapy. Co-author DOI 10.1038/s41575-021-00486-6↗
  13. Regulation and function of autophagy in pancreatic cancer. Co-author DOI 10.1080/15548627.2020.1847462↗
  14. The dark side of ferroptosis in pancreatic cancer. Co-author DOI 10.1080/2162402x.2020.1868691↗
  15. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-320441↗
  16. Mitophagy in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.616079↗
  17. The Art of War: Ferroptosis and Pancreatic Cancer. First author DOI 10.3389/fphar.2021.773909↗
  18. The Dual Role of HMGB1 in Pancreatic Cancer. Co-author DOI 10.1097/jp9.0000000000000002↗
  19. RAGE-specific single chain Fv for PET imaging of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0192821↗
  20. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Co-author DOI 10.1038/cr.2017.51↗
  21. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Co-author DOI 10.1038/cddis.2014.445↗
  22. Autophagy in pancreatic cancer pathogenesis and treatment. Co-author PMID 22860230↗

Grants 1

  1. The Pancreatic Cancer Microenvironment R01CA211070↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daolin Tang · 22 shared papers, 2012–2026 · strength 3.98
  2. Yangchun Xie · 5 shared papers, 2017–2026 · strength 1.02
  3. Jiao Liu · 4 shared papers, 2023–2025 · strength 0.97
  4. Herbert J. Zeh · 7 shared papers, 2014–2025 · strength 0.88
  5. Fangquan Chen · 3 shared papers, 2025 · strength 0.79
  6. Xin Chen · 4 shared papers, 2021–2023 · strength 0.70
  7. Changfeng Li · 2 shared papers, 2025 · strength 0.55
  8. Feimei Kuang · 2 shared papers, 2021–2023 · strength 0.41
  9. Jiao Liu · 2 shared papers, 2021 · strength 0.39
  10. Jiao Liu · 2 shared papers, 2021–2023 · strength 0.39
  11. Michael T. Lotze · 4 shared papers, 2014–2021 · strength 0.30
  12. Xiutao Cai · 1 shared paper, 2025 · strength 0.25
  13. Yuanda Liu · 1 shared paper, 2025 · strength 0.25
  14. Dongwen Que · 1 shared paper, 2023 · strength 0.24
  15. Jiao Liu · 1 shared paper, 2023 · strength 0.24
  16. Jingbo Li · 1 shared paper, 2021 · strength 0.22
  17. Yuan Wang · 1 shared paper, 2023 · strength 0.22
  18. Dexing Zeng · 2 shared papers, 2017–2022 · strength 0.22
  19. Jingbo Li · 1 shared paper, 2023 · strength 0.18
  20. Brent R. Stockwell · 1 shared paper, 2023 · strength 0.18
  21. Jingbo Li · 1 shared paper, 2021 · strength 0.16
  22. Yongkang Gai · 1 shared paper, 2022 · strength 0.16
  23. Lingyi Sun · 1 shared paper, 2022 · strength 0.16
  24. Jin Huang · 1 shared paper, 2021 · strength 0.11
  25. David L. Bartlett · 2 shared papers, 2014–2017 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.